vs
吉利德科学（GILD）与切尼尔能源（LNG）财务数据对比。点击上方公司名可切换其他公司
吉利德科学的季度营收约是切尼尔能源的1.5倍（$7.9B vs $5.4B），切尼尔能源净利率更高（42.8% vs 27.5%，领先15.3%），切尼尔能源同比增速更快（20.3% vs 4.7%），吉利德科学自由现金流更多（$3.1B vs $1.3B），过去两年切尼尔能源的营收复合增速更高（14.3% vs 8.9%）
吉利德科学是总部位于美国加利福尼亚州福斯特城的生物制药企业，专注于研发抗病毒药物，覆盖艾滋病、乙型肝炎、丙型肝炎、流感、新冠等治疗领域，核心产品包括来迪派韦索磷布韦、索磷布韦等，现为纳斯达克100指数及标普100指数成分股。
切尼尔能源（Cheniere Energy, Inc.）是总部位于美国得克萨斯州休斯敦的液化天然气（LNG）企业，专注于液化天然气的生产与供应业务，是北美地区颇具影响力的能源行业参与者。
GILD vs LNG — 直观对比
营收规模更大
GILD
是对方的1.5倍
$5.4B
营收增速更快
LNG
高出15.6%
4.7%
净利率更高
LNG
高出15.3%
27.5%
自由现金流更多
GILD
多$1.8B
$1.3B
两年增速更快
LNG
近两年复合增速
8.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $7.9B | $5.4B |
| 净利润 | $2.2B | $2.3B |
| 毛利率 | 79.5% | — |
| 营业利润率 | 25.0% | 70.8% |
| 净利率 | 27.5% | 42.8% |
| 营收同比 | 4.7% | 20.3% |
| 净利润同比 | 22.4% | 135.6% |
| 每股收益（稀释后） | $1.75 | $10.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GILDLNG
| Q4 25 | $7.9B | $5.4B | ||
| Q3 25 | $7.8B | $4.3B | ||
| Q2 25 | $7.1B | $4.5B | ||
| Q1 25 | $6.7B | $5.3B | ||
| Q4 24 | $7.6B | $4.5B | ||
| Q3 24 | $7.5B | $3.7B | ||
| Q2 24 | $7.0B | $3.1B | ||
| Q1 24 | $6.7B | $4.1B |
净利润GILDLNG
| Q4 25 | $2.2B | $2.3B | ||
| Q3 25 | $3.1B | $1.0B | ||
| Q2 25 | $2.0B | $1.6B | ||
| Q1 25 | $1.3B | $353.0M | ||
| Q4 24 | $1.8B | $977.0M | ||
| Q3 24 | $1.3B | $893.0M | ||
| Q2 24 | $1.6B | $880.0M | ||
| Q1 24 | $-4.2B | $502.0M |
毛利率GILDLNG
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.8% | — |
营业利润率GILDLNG
| Q4 25 | 25.0% | 70.8% | ||
| Q3 25 | 42.8% | 42.3% | ||
| Q2 25 | 34.9% | 56.1% | ||
| Q1 25 | 33.6% | 18.2% | ||
| Q4 24 | 32.4% | 38.9% | ||
| Q3 24 | 11.8% | 44.7% | ||
| Q2 24 | 38.0% | 50.5% | ||
| Q1 24 | -64.6% | 28.0% |
净利率GILDLNG
| Q4 25 | 27.5% | 42.8% | ||
| Q3 25 | 39.3% | 24.4% | ||
| Q2 25 | 27.7% | 36.1% | ||
| Q1 25 | 19.7% | 6.7% | ||
| Q4 24 | 23.6% | 21.9% | ||
| Q3 24 | 16.6% | 24.2% | ||
| Q2 24 | 23.2% | 28.0% | ||
| Q1 24 | -62.4% | 12.2% |
每股收益（稀释后）GILDLNG
| Q4 25 | $1.75 | $10.51 | ||
| Q3 25 | $2.43 | $4.75 | ||
| Q2 25 | $1.56 | $7.30 | ||
| Q1 25 | $1.04 | $1.57 | ||
| Q4 24 | $1.43 | $4.30 | ||
| Q3 24 | $1.00 | $3.93 | ||
| Q2 24 | $1.29 | $3.84 | ||
| Q1 24 | $-3.34 | $2.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $68.0M | $1.1B |
| 总债务越低越好 | $24.9B | $22.5B |
| 股东权益账面价值 | $22.7B | $7.9B |
| 总资产 | $59.0B | $47.9B |
| 负债/权益比越低杠杆越低 | 1.10× | 2.84× |
8季度趋势，按日历期对齐
现金及短期投资GILDLNG
| Q4 25 | $68.0M | $1.1B | ||
| Q3 25 | $19.0M | $1.1B | ||
| Q2 25 | $69.0M | $1.6B | ||
| Q1 25 | — | $2.5B | ||
| Q4 24 | — | $2.6B | ||
| Q3 24 | — | $2.7B | ||
| Q2 24 | — | $2.4B | ||
| Q1 24 | — | $4.4B |
总债务GILDLNG
| Q4 25 | $24.9B | $22.5B | ||
| Q3 25 | $24.9B | $22.0B | ||
| Q2 25 | $24.9B | $22.0B | ||
| Q1 25 | $25.0B | $22.5B | ||
| Q4 24 | $26.7B | $22.6B | ||
| Q3 24 | $23.2B | $22.5B | ||
| Q2 24 | $23.3B | $22.6B | ||
| Q1 24 | $25.2B | $21.4B |
股东权益GILDLNG
| Q4 25 | $22.7B | $7.9B | ||
| Q3 25 | $21.5B | $6.7B | ||
| Q2 25 | $19.7B | $6.7B | ||
| Q1 25 | $19.2B | $5.6B | ||
| Q4 24 | $19.3B | $5.7B | ||
| Q3 24 | $18.5B | $5.1B | ||
| Q2 24 | $18.3B | $4.5B | ||
| Q1 24 | $17.5B | $4.3B |
总资产GILDLNG
| Q4 25 | $59.0B | $47.9B | ||
| Q3 25 | $58.5B | $45.1B | ||
| Q2 25 | $55.7B | $44.6B | ||
| Q1 25 | $56.4B | $43.5B | ||
| Q4 24 | $59.0B | $43.9B | ||
| Q3 24 | $54.5B | $43.1B | ||
| Q2 24 | $53.6B | $42.3B | ||
| Q1 24 | $56.3B | $42.9B |
负债/权益比GILDLNG
| Q4 25 | 1.10× | 2.84× | ||
| Q3 25 | 1.16× | 3.25× | ||
| Q2 25 | 1.27× | 3.28× | ||
| Q1 25 | 1.30× | 4.03× | ||
| Q4 24 | 1.38× | 3.96× | ||
| Q3 24 | 1.26× | 4.42× | ||
| Q2 24 | 1.28× | 5.06× | ||
| Q1 24 | 1.44× | 5.04× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.3B | $2.1B |
| 自由现金流经营现金流 - 资本支出 | $3.1B | $1.3B |
| 自由现金流率自由现金流/营收 | 39.4% | 24.4% |
| 资本支出强度资本支出/营收 | 2.6% | 13.8% |
| 现金转化率经营现金流/净利润 | 1.52× | 0.89× |
| 过去12个月自由现金流最近4个季度 | $9.5B | $2.5B |
8季度趋势，按日历期对齐
经营现金流GILDLNG
| Q4 25 | $3.3B | $2.1B | ||
| Q3 25 | $4.1B | $1.4B | ||
| Q2 25 | $827.0M | $831.0M | ||
| Q1 25 | $1.8B | $1.2B | ||
| Q4 24 | $3.0B | $1.6B | ||
| Q3 24 | $4.3B | $1.4B | ||
| Q2 24 | $1.3B | $1.1B | ||
| Q1 24 | $2.2B | $1.2B |
自由现金流GILDLNG
| Q4 25 | $3.1B | $1.3B | ||
| Q3 25 | $4.0B | $738.0M | ||
| Q2 25 | $720.0M | $-193.0M | ||
| Q1 25 | $1.7B | $605.0M | ||
| Q4 24 | $2.8B | $1.1B | ||
| Q3 24 | $4.2B | $875.0M | ||
| Q2 24 | $1.2B | $613.0M | ||
| Q1 24 | $2.1B | $596.0M |
自由现金流率GILDLNG
| Q4 25 | 39.4% | 24.4% | ||
| Q3 25 | 51.0% | 17.2% | ||
| Q2 25 | 10.2% | -4.3% | ||
| Q1 25 | 24.8% | 11.4% | ||
| Q4 24 | 37.4% | 24.0% | ||
| Q3 24 | 55.2% | 23.8% | ||
| Q2 24 | 17.2% | 19.5% | ||
| Q1 24 | 31.6% | 14.5% |
资本支出强度GILDLNG
| Q4 25 | 2.6% | 13.8% | ||
| Q3 25 | 1.9% | 16.0% | ||
| Q2 25 | 1.5% | 22.7% | ||
| Q1 25 | 1.6% | 11.8% | ||
| Q4 24 | 1.9% | 12.7% | ||
| Q3 24 | 1.9% | 14.0% | ||
| Q2 24 | 1.9% | 16.0% | ||
| Q1 24 | 1.6% | 15.8% |
现金转化率GILDLNG
| Q4 25 | 1.52× | 0.89× | ||
| Q3 25 | 1.35× | 1.36× | ||
| Q2 25 | 0.42× | 0.51× | ||
| Q1 25 | 1.34× | 3.48× | ||
| Q4 24 | 1.67× | 1.68× | ||
| Q3 24 | 3.44× | 1.56× | ||
| Q2 24 | 0.82× | 1.27× | ||
| Q1 24 | — | 2.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
LNG
| Liquefied Natural Gas | $5.3B | 99% |
| Other | $103.0M | 2% |
| Regasification Service | $34.0M | 1% |
